Second varicella vaccine dose [4]

Pediatric Infectious Disease Journal

Volumn 26, Issue 2, 2007, Pages 193-194

  Kuter, Barbara ^a   Schodel, Florian ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHICKENPOX MEASLES MUMPS RUBELLA VACCINE; CHICKENPOX VACCINE; GLYCOPROTEIN;

ANTIBODY TITER; CHICKENPOX; CLINICAL TRIAL; CORRELATION ANALYSIS; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; HUMAN; IMMUNIZATION; IMMUNOGENICITY; LETTER; PRIORITY JOURNAL; PROTECTION; SEROCONVERSION; SINGLE DRUG DOSE; VIRUS TITRATION;

CHICKENPOX; CHICKENPOX VACCINE; HUMANS; IMMUNIZATION, SECONDARY;

EID: 33846643964     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000253042.84984.01     Document Type: Letter

References (16)

1. Arvin A, Gershon A. Control of varicella: Why is a 2-dose schedule necessary? Pediatr Infect Dis J. 2006;25:475-476.
2. Centers for Disease Control and Prevention. Provisional Statement of the Advisory Committee on Immunization Practices. July 2006. ACIP web site.
3. Weibel R, Neff BJ, Kuter BJ, et al. Live attenuated varicella virus vaccine: Efficacy trial in healthy children. N Engl J Med. 1984;310:1409-1415.
4. White CJ, Kuter BJ, Hildebrand CS, et al. Varicella vaccine (VARIVAX) in healthy children and adolescents: Results from clinical trials, 1987 to 1989. Pediatrics. 1991;87:604-610.
5. Wasmuth EH, Miller WL. Sensitive enzyme-linked immunosorbent assay for antibody to varicella-zoster virus using purified VZV glycoprotein antigen. J Med Virol. 1990;32:189-193.
6. Krah DL. Assays for antibodies to varicella-zoster virus. Infect Dis Clin North Am. 1996;10:507-527.
7. Provost PJ, Krah DL, Kuter BJ, et al. Antibody assays suitable for assessing immune responses to live varicella vaccine. Vaccine. 1991;9:111-116.
8. Li S, Chan ISF, Matthew H, et al. Inverse relationship between six week postvaccination varicella antibody response to vaccine and likelihood of long term breakthrough infection. Pediatr Infect Dis J. 2002;21:337-342.
9. Vessey SR, Chan CY, Kuter BJ, et al. Childhood vaccination against varicella: Persistence of antibody, duration of protection, and vaccine efficacy. J Pediatr. 2001;139:297-304.
10. Package circular for VARIVAX (Varicella Virus Vaccine Live [Oka/Merck]). Whitehouse Station, NJ: Merck & Co, Inc; April 2006.
11. Krause PR, Kinman DM. Efficacy, immunogenicity, safety, and use of live attenuated chickenpox vaccine. J Pediatr. 1995;127:518-525.
12. Seward JF, Watson BM, Peterson CL, et al. Varicella disease after introduction of varicella vaccine in the United States, 1995-2000. JAMA. 2002;287:606-611.
13. Kuter B, Matthews H, Shinefield H, et al. Ten year follow-up of healthy children who received one or two injections of varicella vaccine. Pediatr Infect Dis J. 2004;23:132-137.
14. Shinefield H, Williams WR, Marchant C, et al. Dose-response study of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children. Pediatr Infect Dis J. 2005;24:760-675.
15. Shinefield H, Black S, Digilio L, et al. Evaluation of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children. Pediatr Infect Dis J. 2005;24:665-669.
16. Kuter BJ, Hoffman Brown M, Hartzel J, et al. Overview of the safety and immunogenicity of the newly licensed combination measles, mumps, rubella, and varicella vaccine (ProQuad®). Human Vaccines. 2006;2:205-214.